Australia's most trusted
source of pharma news
Posted 20 December 2021 AM
AstraZeneca is first out of the gate for 2022, announcing Forxiga will be listed on the PBS from New Years Day providing Australians living with heart failure broader access to another treatment option that may help to reduce the number of hospitalisations and cardiovascular deaths.
Despite efforts to improve quality of life and survival, patients with heart failure continue to have a poor prognosis with cumulative mortality of approximately 31 per cent at one year and 50 per cent at five years.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.